Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Strategic Exit?

<< Previous

Bullboard Posts

Next >>

Post by hammerman15on Nov 26, 2020 3:23pm

907 Views

Post# 31982794

Strategic Exit?

Dan mentioned a strategic exit of otena.... Does that mean a buyout just for otena ? And then Antibe is out completely on anything otena in the future? Assuming it would be a few billion would that equate to that much in market cap?

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 27, 2024